DNA repair inhibitors: where do we go from here?
DNA repair inhibitors: where do we go from here?
复制标题
DNA 修复抑制剂：我们下一步该何去何从？
DOI：
10.1016/j.dnarep.2011.09.003
复制
发表时间：
2011
期刊：
影响因子：
3.8
通讯作者：
Kelley,MarkR
中科院分区：
文献类型：
--
作者：
Kelley,MarkR
1.背景尽管靶向DNA修复抑制剂作为癌症疗法的使用在许多方面还处于起步阶段，但在增强其用途和效用方面正在取得许多进展。这样做存在许多挑战，因为这涉及识别预后和预测生物标志物，然后开发可作为单一药物或其他抗癌药物的增强剂的选择性 DNA 修复抑制剂。这些集体努力的成功取决于对 DNA 损伤反应和修复途径如何在正常组织和肿瘤组织中发挥作用的更深入的了解。
1. BackgroundAlthough the use of targeted DNA repair inhibitors as cancer therapies is, in many ways, in its infancy, many strides are being made to augment their use and utility. Many challenges exist in doing so, as this involves identifying prognostic and predictive biomarkers, then developing selective DNA repair inhibitors that can act as single agents or potentiators of other anticancer agents. The success of these collective efforts hinges on a deeper understanding of how DNA damage response and repair pathways work in both normal and tumor tissues.